Table 1.

Cytokine production byMLRCD4+ T cells

StimuliCellsIL-2IL-4IL-10TGF-β1
Allogeneic TCD PBMCs Pre-G CD4+ 30  (22-38)* < 10* 80  (40-190)* 3800  (3430-4500)* 
  6%  (3%-7%) 2%  (1%-2.5%) 2%  (1.5%-3.5%) 6%  (4%-7%) 
Allogeneic TCD PBMCs Post-G CD4+ < 10*, < 10* 178  (90-250)*, 3040  (2200-4075)* 
  < 1%, < 1%, 12%  (8%-18%), 5%  (4%-8%) 
StimuliCellsIL-2IL-4IL-10TGF-β1
Allogeneic TCD PBMCs Pre-G CD4+ 30  (22-38)* < 10* 80  (40-190)* 3800  (3430-4500)* 
  6%  (3%-7%) 2%  (1%-2.5%) 2%  (1.5%-3.5%) 6%  (4%-7%) 
Allogeneic TCD PBMCs Post-G CD4+ < 10*, < 10* 178  (90-250)*, 3040  (2200-4075)* 
  < 1%, < 1%, 12%  (8%-18%), 5%  (4%-8%) 

Ranges appear in parentheses.

Pre-G and post-G CD4+ T cells from the same donor were activated with allogeneic TCD PBMCs for 7 days in MLR at a 1:3 stimulator-responder ratio. After culture, IL-2, IL-4, IL-10, and TGF-β1 levels were measured by ELISA in culture supernatants, whereas the frequency of cytokine-producing CD4+ T cells was determined by flow cytometry after short-term exposure to a protein transport inhibitor (see “Patients, materials, and methods”). Binding specificities of the anticytokine mAb were established by adding recombinant cytokines before mAb staining (data not shown). All determinations were performed in triplicate. Data were reported as median values and ranges and are representative of 6 independent experiments.

*

pg/mL.

Percentage positive cells.

P < .05 compared with pre-GMLRCD4+ T cells.

Close Modal

or Create an Account

Close Modal
Close Modal